Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Niguldipine

Targets (1)Biointeractions (1)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Niguldipine

Accession Number

DB09239

Type

Small Molecule

Groups

Experimental

Description

Niguldipine is a calcium channel blocker and a1-adrenergic receptor antagonist.

Structure

Similar Structures

Synonyms

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Niguldipine hydrochloride	1G8C7QS9SR	113145-69-0	MHOSUIMBPQVOEU-WAQYZQTGSA-N

Categories

UNII

Z81N45O25Z

CAS number

113165-32-5

Weight

Average: 609.723
Monoisotopic: 609.283885988

Chemical Formula

C₃₆H₃₉N₃O₆

InChI Key

SVJMLYUFVDMUHP-XIFFEERXSA-N

InChI

InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m0/s1

IUPAC Name

3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

SMILES

[H]N1C(C)=C([[email protected]](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Target	Actions	Organism
UAlpha-1A adrenergic receptor	antagonist	Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2-HYDROXY-1,4-NAPHTHOQUINONE	The therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Niguldipine.	Experimental
2-mercaptobenzothiazole	The therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Niguldipine.	Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Niguldipine.	Experimental
Acebutolol	Acebutolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Acemetacin	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Acemetacin.	Approved, Experimental, Investigational
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Niguldipine.	Approved
Acetyldigoxin	Acetyldigoxin may decrease the cardiotoxic activities of Niguldipine.	Experimental
Alfuzosin	Alfuzosin may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Aliskiren	Aliskiren may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Alprenolol	Alprenolol may increase the hypotensive activities of Niguldipine.	Approved, Withdrawn
Ambrisentan	Niguldipine may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amifostine	Niguldipine may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amlodipine	Amlodipine may increase the hypotensive activities of Niguldipine.	Approved
Amobarbital	The metabolism of Niguldipine can be increased when combined with Amobarbital.	Approved, Illicit
Amorolfine	The therapeutic efficacy of Amorolfine can be increased when used in combination with Niguldipine.	Approved, Investigational
Amphetamine	Amphetamine may increase the hypotensive activities of Niguldipine.	Approved, Illicit, Investigational
Amphotericin B	The therapeutic efficacy of Amphotericin B can be increased when used in combination with Niguldipine.	Approved, Investigational
Ancestim	The risk or severity of cytotoxicity can be increased when Ancestim is combined with Niguldipine.	Approved, Investigational, Withdrawn
Anidulafungin	The therapeutic efficacy of Anidulafungin can be increased when used in combination with Niguldipine.	Approved, Investigational
Arotinolol	The risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Niguldipine.	Investigational
Artemether	The therapeutic efficacy of Artemether can be increased when used in combination with Niguldipine.	Approved
Atenolol	Atenolol may increase the hypotensive activities of Niguldipine.	Approved
Avanafil	Avanafil may increase the antihypertensive activities of Niguldipine.	Approved
Bafilomycin A1	The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Niguldipine.	Experimental
Barbexaclone	The metabolism of Niguldipine can be increased when combined with Barbexaclone.	Experimental
Barbital	The metabolism of Niguldipine can be increased when combined with Barbital.	Illicit
Barnidipine	Niguldipine may increase the antihypertensive activities of Barnidipine.	Approved
Benazepril	Benazepril may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Bendroflumethiazide	Bendroflumethiazide may increase the hypotensive activities of Niguldipine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Niguldipine.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be increased when used in combination with Niguldipine.	Approved, Investigational
Bepridil	Bepridil may increase the hypotensive activities of Niguldipine.	Approved, Withdrawn
Betaxolol	Betaxolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Bethanidine	Bethanidine may increase the hypotensive activities of Niguldipine.	Approved
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Niguldipine.	Approved, Investigational
Bietaserpine	Bietaserpine may increase the hypotensive activities of Niguldipine.	Experimental
Bifonazole	The therapeutic efficacy of Bifonazole can be increased when used in combination with Niguldipine.	Approved, Investigational
Bimatoprost	Bimatoprost may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Bisoprolol	Bisoprolol may increase the hypotensive activities of Niguldipine.	Approved
Bosentan	Bosentan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
BQ-123	Niguldipine may increase the hypotensive activities of BQ-123.	Investigational
Brefeldin A	The therapeutic efficacy of Brefeldin A can be increased when used in combination with Niguldipine.	Experimental
Bretylium	Bretylium may increase the hypotensive activities of Niguldipine.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Niguldipine.	Approved
Brofaromine	Brofaromine may increase the hypotensive activities of Niguldipine.	Experimental
Bucindolol	The risk or severity of hypotension can be increased when Bucindolol is combined with Niguldipine.	Investigational
Bunazosin	The risk or severity of hypotension can be increased when Bunazosin is combined with Niguldipine.	Investigational
Bupranolol	Bupranolol may increase the hypotensive activities of Niguldipine.	Approved
Butenafine	The therapeutic efficacy of Butenafine can be increased when used in combination with Niguldipine.	Approved
Butoconazole	The therapeutic efficacy of Butoconazole can be increased when used in combination with Niguldipine.	Approved
Cabazitaxel	The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niguldipine.	Approved
Cadralazine	Cadralazine may increase the hypotensive activities of Niguldipine.	Experimental
Cafedrine	Niguldipine may increase the hypotensive activities of Cafedrine.	Investigational
Calcium Acetate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Acetate.	Approved, Investigational
Calcium Chloride	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Chloride.	Approved
Calcium Citrate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Citrate.	Approved
Calcium glubionate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium glubionate.	Approved
Calcium Gluceptate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Gluceptate.	Approved
Calcium gluconate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium gluconate.	Approved, Vet Approved
Calcium lactate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium lactate.	Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium lactate gluconate.	Experimental
Calcium levulinate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium levulinate.	Approved, Experimental
Calcium pangamate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium pangamate.	Experimental
Calcium Phosphate	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Phosphate.	Approved
Candesartan	Niguldipine may increase the hypotensive activities of Candesartan.	Experimental
Candesartan cilexetil	Candesartan cilexetil may increase the hypotensive activities of Niguldipine.	Approved
Candicidin	The therapeutic efficacy of Candicidin can be increased when used in combination with Niguldipine.	Withdrawn
Candoxatril	Candoxatril may increase the hypotensive activities of Niguldipine.	Experimental
Capric acid	The therapeutic efficacy of Capric acid can be increased when used in combination with Niguldipine.	Experimental
Captopril	Captopril may increase the hypotensive activities of Niguldipine.	Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Niguldipine.	Withdrawn
Carteolol	Carteolol may increase the hypotensive activities of Niguldipine.	Approved
Carvedilol	Carvedilol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Casein	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Casein.	Approved
Caspofungin	The therapeutic efficacy of Caspofungin can be increased when used in combination with Niguldipine.	Approved
Celiprolol	Celiprolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Cerulenin	The therapeutic efficacy of Cerulenin can be increased when used in combination with Niguldipine.	Approved
Chlorothiazide	Chlorothiazide may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Chloroxine	The therapeutic efficacy of Chloroxine can be increased when used in combination with Niguldipine.	Approved
Chlorthalidone	Chlorthalidone may increase the hypotensive activities of Niguldipine.	Approved
Cicletanine	Niguldipine may increase the hypotensive activities of Cicletanine.	Investigational
Ciclopirox	The therapeutic efficacy of Ciclopirox can be increased when used in combination with Niguldipine.	Approved, Investigational
Cilazapril	Cilazapril may increase the hypotensive activities of Niguldipine.	Approved
Cimetidine	The serum concentration of Niguldipine can be increased when it is combined with Cimetidine.	Approved, Investigational
Clonidine	Clonidine may increase the hypotensive activities of Niguldipine.	Approved
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niguldipine.	Approved
Cloranolol	Niguldipine may increase the hypotensive activities of Cloranolol.	Experimental
Clotrimazole	The therapeutic efficacy of Clotrimazole can be increased when used in combination with Niguldipine.	Approved, Vet Approved
Cordycepin	The therapeutic efficacy of Cordycepin can be increased when used in combination with Niguldipine.	Investigational
Cryptenamine	Cryptenamine may increase the hypotensive activities of Niguldipine.	Approved
Cyclopenthiazide	Niguldipine may increase the hypotensive activities of Cyclopenthiazide.	Experimental
Cyclophosphamide	Cyclophosphamide may increase the cardiotoxic activities of Niguldipine.	Approved, Investigational
Cyclosporine	The therapeutic efficacy of Cyclosporine can be increased when used in combination with Niguldipine.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Niguldipine.	Approved
Cymarin	Cymarin may decrease the cardiotoxic activities of Niguldipine.	Experimental
Debrisoquin	Debrisoquin may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Delapril	Niguldipine may increase the hypotensive activities of Delapril.	Experimental
Deserpidine	Niguldipine may increase the hypotensive activities of Deserpidine.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Niguldipine.	Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Niguldipine.	Approved
Dichlorophene	The therapeutic efficacy of Dichlorophene can be increased when used in combination with Niguldipine.	Vet Approved
Diethylnorspermine	Diethylnorspermine may increase the hypotensive activities of Niguldipine.	Investigational
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Niguldipine.	Approved, Investigational
Digoxin	Digoxin may decrease the cardiotoxic activities of Niguldipine.	Approved
Digoxin Immune Fab (Ovine)	Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Niguldipine.	Approved
Dihydralazine	Dihydralazine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Diltiazem	Diltiazem may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Docetaxel	The risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.	Approved, Investigational
Dorzolamide	Dorzolamide may increase the hypotensive activities of Niguldipine.	Approved
Doxazosin	Doxazosin may increase the hypotensive activities of Niguldipine.	Approved
Econazole	The therapeutic efficacy of Econazole can be increased when used in combination with Niguldipine.	Approved
Efavirenz	The serum concentration of Niguldipine can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The therapeutic efficacy of Efinaconazole can be increased when used in combination with Niguldipine.	Approved
Efonidipine	Efonidipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Enalapril	Enalapril may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Enalaprilat	Niguldipine may increase the hypotensive activities of Enalaprilat.	Approved
Endralazine	Endralazine may increase the hypotensive activities of Niguldipine.	Experimental
Epanolol	Niguldipine may increase the hypotensive activities of Epanolol.	Experimental
Epoprostenol	Epoprostenol may increase the hypotensive activities of Niguldipine.	Approved
Eprosartan	Eprosartan may increase the hypotensive activities of Niguldipine.	Approved
Felodipine	Felodipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Fenoldopam	Fenoldopam may increase the hypotensive activities of Niguldipine.	Approved
Fenticonazole	The therapeutic efficacy of Fenticonazole can be increased when used in combination with Niguldipine.	Experimental
Ferulic acid	Ferulic acid may increase the hypotensive activities of Niguldipine.	Experimental
Fluconazole	The therapeutic efficacy of Fluconazole can be increased when used in combination with Niguldipine.	Approved, Investigational
Flucytosine	The therapeutic efficacy of Flucytosine can be increased when used in combination with Niguldipine.	Approved, Investigational
Flutrimazole	The therapeutic efficacy of Flutrimazole can be increased when used in combination with Niguldipine.	Experimental
Fosinopril	Fosinopril may increase the hypotensive activities of Niguldipine.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Niguldipine.	Approved, Investigational, Vet Approved
Gitoformate	Gitoformate may decrease the cardiotoxic activities of Niguldipine.	Experimental
Glyphosate	The therapeutic efficacy of Glyphosate can be increased when used in combination with Niguldipine.	Experimental
Griseofulvin	The therapeutic efficacy of Griseofulvin can be increased when used in combination with Niguldipine.	Approved, Investigational, Vet Approved
Guanabenz	Guanabenz may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Guanadrel	Guanadrel may increase the hypotensive activities of Niguldipine.	Approved
Guanazodine	Niguldipine may increase the hypotensive activities of Guanazodine.	Experimental
Guanethidine	Guanethidine may increase the hypotensive activities of Niguldipine.	Approved
Guanfacine	Guanfacine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Guanoclor	Niguldipine may increase the hypotensive activities of Guanoclor.	Experimental
Guanoxabenz	Niguldipine may increase the hypotensive activities of Guanoxabenz.	Experimental
Guanoxan	Niguldipine may increase the hypotensive activities of Guanoxan.	Experimental
Hachimycin	The therapeutic efficacy of Hachimycin can be increased when used in combination with Niguldipine.	Experimental
Haloprogin	The therapeutic efficacy of Haloprogin can be increased when used in combination with Niguldipine.	Approved, Withdrawn
Harmaline	Harmaline may increase the hypotensive activities of Niguldipine.	Experimental
Hexamethonium	Hexamethonium may increase the hypotensive activities of Niguldipine.	Experimental
Hexetidine	The therapeutic efficacy of Hexetidine can be increased when used in combination with Niguldipine.	Approved, Investigational
Hexobarbital	The metabolism of Niguldipine can be increased when combined with Hexobarbital.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Niguldipine.	Experimental
Hydralazine	Hydralazine may increase the hypotensive activities of Niguldipine.	Approved
Hydrochlorothiazide	Hydrochlorothiazide may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Iloprost	Iloprost may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Imidapril	Niguldipine may increase the hypotensive activities of Imidapril.	Investigational
Indapamide	Indapamide may increase the hypotensive activities of Niguldipine.	Approved
Indenolol	Indenolol may increase the hypotensive activities of Niguldipine.	Withdrawn
Indoramin	Indoramin may increase the hypotensive activities of Niguldipine.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Niguldipine.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Niguldipine.	Withdrawn
Irbesartan	Irbesartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Niguldipine.	Approved
Isoconazole	The therapeutic efficacy of Isoconazole can be increased when used in combination with Niguldipine.	Approved
Isradipine	Isradipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Itraconazole	The therapeutic efficacy of Itraconazole can be increased when used in combination with Niguldipine.	Approved, Investigational
Ketanserin	Ketanserin may increase the hypotensive activities of Niguldipine.	Investigational
Ketoconazole	The therapeutic efficacy of Ketoconazole can be increased when used in combination with Niguldipine.	Approved, Investigational
Labetalol	Labetalol may increase the hypotensive activities of Niguldipine.	Approved
Lacidipine	Lacidipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Lanatoside C	Lanatoside C may decrease the cardiotoxic activities of Niguldipine.	Experimental
Latanoprost	Latanoprost may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Lercanidipine	Lercanidipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Linsidomine	Niguldipine may increase the hypotensive activities of Linsidomine.	Experimental
Lisinopril	Lisinopril may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Lofexidine	Lofexidine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Losartan	Losartan may increase the hypotensive activities of Niguldipine.	Approved
Macitentan	Niguldipine may increase the hypotensive activities of Macitentan.	Approved
Magnesium hydroxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium salicylate.	Approved
Magnesium sulfate	The risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium sulfate.	Approved, Investigational, Vet Approved
Manidipine	Manidipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Mecamylamine	Mecamylamine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Mepartricin	The therapeutic efficacy of Mepartricin can be increased when used in combination with Niguldipine.	Experimental
Methohexital	The metabolism of Niguldipine can be increased when combined with Methohexital.	Approved
Methoserpidine	Niguldipine may increase the hypotensive activities of Methoserpidine.	Experimental
Methyldopa	Methyldopa may increase the hypotensive activities of Niguldipine.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Niguldipine.	Approved, Investigational
Methylphenobarbital	The metabolism of Niguldipine can be increased when combined with Methylphenobarbital.	Approved
Metildigoxin	Metildigoxin may decrease the cardiotoxic activities of Niguldipine.	Experimental
Metipranolol	Metipranolol may increase the hypotensive activities of Niguldipine.	Approved
Metolazone	Metolazone may increase the hypotensive activities of Niguldipine.	Approved
Metoprolol	Metoprolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Metyrosine	Niguldipine may increase the hypotensive activities of Metyrosine.	Approved
Mevastatin	The therapeutic efficacy of Mevastatin can be increased when used in combination with Niguldipine.	Experimental
Mibefradil	Mibefradil may increase the hypotensive activities of Niguldipine.	Investigational, Withdrawn
Micafungin	The therapeutic efficacy of Micafungin can be increased when used in combination with Niguldipine.	Approved, Investigational
Miconazole	The therapeutic efficacy of Miconazole can be increased when used in combination with Niguldipine.	Approved, Investigational, Vet Approved
Miltefosine	The therapeutic efficacy of Miltefosine can be increased when used in combination with Niguldipine.	Approved, Investigational
Minaprine	Minaprine may increase the hypotensive activities of Niguldipine.	Approved
Minoxidil	Minoxidil may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Mirodenafil	Mirodenafil may increase the antihypertensive activities of Niguldipine.	Investigational
Moclobemide	Moclobemide may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Moexipril	Moexipril may increase the hypotensive activities of Niguldipine.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Monensin	The therapeutic efficacy of Monensin can be increased when used in combination with Niguldipine.	Vet Approved
Moxonidine	Moxonidine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Muzolimine	Niguldipine may increase the hypotensive activities of Muzolimine.	Experimental
Myxothiazol	The therapeutic efficacy of Myxothiazol can be increased when used in combination with Niguldipine.	Experimental
Nadolol	Nadolol may increase the hypotensive activities of Niguldipine.	Approved
Nafcillin	The therapeutic efficacy of Niguldipine can be decreased when used in combination with Nafcillin.	Approved, Investigational
Naftifine	The therapeutic efficacy of Naftifine can be increased when used in combination with Niguldipine.	Approved
Naftopidil	Niguldipine may increase the hypotensive activities of Naftopidil.	Investigational
Natamycin	The therapeutic efficacy of Natamycin can be increased when used in combination with Niguldipine.	Approved
Nebivolol	Nebivolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Nialamide	Nialamide may increase the hypotensive activities of Niguldipine.	Withdrawn
Nicardipine	Nicardipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Nicorandil	Nicorandil may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Nifuratel	The therapeutic efficacy of Nifuratel can be increased when used in combination with Niguldipine.	Experimental
Nikkomycin Z	The therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Niguldipine.	Investigational
Nilvadipine	Nilvadipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Nimodipine	Nimodipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Nisoldipine	Nisoldipine may increase the hypotensive activities of Niguldipine.	Approved
Nitrendipine	Nitrendipine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Nitroprusside	Niguldipine may increase the hypotensive activities of Nitroprusside.	Approved, Investigational
Nitroxoline	The therapeutic efficacy of Nitroxoline can be increased when used in combination with Niguldipine.	Approved
Nystatin	The therapeutic efficacy of Nystatin can be increased when used in combination with Niguldipine.	Approved, Vet Approved
Obinutuzumab	Niguldipine may increase the hypotensive activities of Obinutuzumab.	Approved, Investigational
Octamoxin	Octamoxin may increase the hypotensive activities of Niguldipine.	Withdrawn
Oleandrin	Oleandrin may decrease the cardiotoxic activities of Niguldipine.	Experimental, Investigational
Olmesartan	Olmesartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Omapatrilat	Omapatrilat may increase the hypotensive activities of Niguldipine.	Investigational
Omoconazole	The therapeutic efficacy of Omoconazole can be increased when used in combination with Niguldipine.	Experimental
Ouabain	Ouabain may decrease the cardiotoxic activities of Niguldipine.	Approved
Oxiconazole	The therapeutic efficacy of Oxiconazole can be increased when used in combination with Niguldipine.	Approved
Oxprenolol	Oxprenolol may increase the hypotensive activities of Niguldipine.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Niguldipine.	Approved, Vet Approved
Pafuramidine	The therapeutic efficacy of Pafuramidine can be increased when used in combination with Niguldipine.	Investigational
Pargyline	Pargyline may increase the hypotensive activities of Niguldipine.	Approved
Penbutolol	Penbutolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Pentamidine	The therapeutic efficacy of Pentamidine can be increased when used in combination with Niguldipine.	Approved, Investigational
Pentobarbital	The metabolism of Niguldipine can be increased when combined with Pentobarbital.	Approved, Investigational, Vet Approved
Pentolinium	Pentolinium may increase the hypotensive activities of Niguldipine.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Perindopril	Perindopril may increase the hypotensive activities of Niguldipine.	Approved
Peruvoside	Peruvoside may decrease the cardiotoxic activities of Niguldipine.	Experimental
Phenelzine	Phenelzine may increase the hypotensive activities of Niguldipine.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Phenobarbital	The metabolism of Niguldipine can be increased when combined with Phenobarbital.	Approved, Investigational
Phenoxybenzamine	Phenoxybenzamine may increase the hypotensive activities of Niguldipine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Phentolamine	Phentolamine may increase the hypotensive activities of Niguldipine.	Approved
Pinacidil	Pinacidil may increase the hypotensive activities of Niguldipine.	Approved
Pindolol	Pindolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Niguldipine.	Approved
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Platelet Activating Factor	Platelet Activating Factor may increase the hypotensive activities of Niguldipine.	Experimental
Polythiazide	Polythiazide may increase the hypotensive activities of Niguldipine.	Approved
Posaconazole	The therapeutic efficacy of Posaconazole can be increased when used in combination with Niguldipine.	Approved, Investigational, Vet Approved
Prazosin	Prazosin may increase the hypotensive activities of Niguldipine.	Approved
Primidone	The metabolism of Niguldipine can be increased when combined with Primidone.	Approved, Vet Approved
Procarbazine	Procarbazine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Propranolol	Propranolol may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Proscillaridin	Proscillaridin may decrease the cardiotoxic activities of Niguldipine.	Experimental
Pyrrolnitrin	The therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Niguldipine.	Experimental
Quinapril	Quinapril may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Quinine	Quinine may increase the hypotensive activities of Niguldipine.	Approved
Radicicol	The therapeutic efficacy of Radicicol can be increased when used in combination with Niguldipine.	Experimental
Ramipril	Ramipril may increase the hypotensive activities of Niguldipine.	Approved
Rasagiline	Rasagiline may increase the hypotensive activities of Niguldipine.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Niguldipine.	Approved
Rescinnamine	Niguldipine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	Reserpine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Rifabutin	The risk or severity of hypotension can be increased when Rifabutin is combined with Niguldipine.	Approved, Investigational
Rifampicin	The risk or severity of hypotension can be increased when Rifampicin is combined with Niguldipine.	Approved
Rifapentine	The risk or severity of hypotension can be increased when Rifapentine is combined with Niguldipine.	Approved, Investigational
Rifaximin	The risk or severity of hypotension can be increased when Rifaximin is combined with Niguldipine.	Approved, Investigational
Rilmenidine	Rilmenidine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Riociguat	Niguldipine may increase the hypotensive activities of Riociguat.	Approved
Rituximab	Niguldipine may increase the hypotensive activities of Rituximab.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Niguldipine.	Withdrawn
Salicylhydroxamic Acid	The therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Niguldipine.	Experimental
Salicylic acid	The therapeutic efficacy of Salicylic acid can be increased when used in combination with Niguldipine.	Approved, Investigational, Vet Approved
Saprisartan	Saprisartan may increase the hypotensive activities of Niguldipine.	Experimental
Secobarbital	The metabolism of Niguldipine can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Niguldipine.	Approved, Investigational, Vet Approved
Selexipag	Niguldipine may increase the hypotensive activities of Selexipag.	Approved
Sertaconazole	The therapeutic efficacy of Sertaconazole can be increased when used in combination with Niguldipine.	Approved, Investigational
Sildenafil	Sildenafil may increase the antihypertensive activities of Niguldipine.	Approved, Investigational
Silodosin	The risk or severity of hypotension can be increased when Silodosin is combined with Niguldipine.	Approved
Sinefungin	The therapeutic efficacy of Sinefungin can be increased when used in combination with Niguldipine.	Experimental
Sirolimus	The therapeutic efficacy of Sirolimus can be increased when used in combination with Niguldipine.	Approved, Investigational
Sitaxentan	Niguldipine may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Spirapril	Spirapril may increase the hypotensive activities of Niguldipine.	Approved
Sulconazole	The therapeutic efficacy of Sulconazole can be increased when used in combination with Niguldipine.	Approved
Tadalafil	Tadalafil may increase the antihypertensive activities of Niguldipine.	Approved, Investigational
Talinolol	Niguldipine may increase the hypotensive activities of Talinolol.	Investigational
Tamsulosin	The risk or severity of hypotension can be increased when Tamsulosin is combined with Niguldipine.	Approved, Investigational
Tavaborole	The therapeutic efficacy of Tavaborole can be increased when used in combination with Niguldipine.	Approved, Investigational
Telmisartan	Telmisartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Temocapril	Temocapril may increase the hypotensive activities of Niguldipine.	Experimental, Investigational
Terazosin	The risk or severity of hypotension can be increased when Terazosin is combined with Niguldipine.	Approved
Terbinafine	The therapeutic efficacy of Terbinafine can be increased when used in combination with Niguldipine.	Approved, Investigational, Vet Approved
Terconazole	The therapeutic efficacy of Terconazole can be increased when used in combination with Niguldipine.	Approved
Terlipressin	Terlipressin may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Tetrahydropalmatine	Niguldipine may increase the hypotensive activities of Tetrahydropalmatine.	Investigational
Theodrenaline	Niguldipine may increase the hypotensive activities of Theodrenaline.	Investigational
Thiamylal	The metabolism of Niguldipine can be increased when combined with Thiamylal.	Approved, Vet Approved
Thiopental	The metabolism of Niguldipine can be increased when combined with Thiopental.	Approved, Vet Approved
Thymol	The therapeutic efficacy of Thymol can be increased when used in combination with Niguldipine.	Approved
Tibolone	Tibolone may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Ticrynafen	Ticrynafen may increase the hypotensive activities of Niguldipine.	Withdrawn
Timolol	Timolol may increase the hypotensive activities of Niguldipine.	Approved
Tioconazole	The therapeutic efficacy of Tioconazole can be increased when used in combination with Niguldipine.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Tolciclate	The therapeutic efficacy of Tolciclate can be increased when used in combination with Niguldipine.	Experimental
Tolnaftate	The therapeutic efficacy of Tolnaftate can be increased when used in combination with Niguldipine.	Approved, Investigational, Vet Approved
Tolonidine	Niguldipine may increase the hypotensive activities of Tolonidine.	Experimental
Toloxatone	Toloxatone may increase the hypotensive activities of Niguldipine.	Approved
Torasemide	Torasemide may increase the hypotensive activities of Niguldipine.	Approved
Trandolapril	Trandolapril may increase the hypotensive activities of Niguldipine.	Approved
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Niguldipine.	Approved, Investigational
Travoprost	Travoprost may increase the hypotensive activities of Niguldipine.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Niguldipine.	Approved, Vet Approved
Trimazosin	Trimazosin may increase the hypotensive activities of Niguldipine.	Experimental
Trimethaphan	Trimethaphan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Trimetrexate	The therapeutic efficacy of Trimetrexate can be increased when used in combination with Niguldipine.	Approved, Investigational
Udenafil	Udenafil may increase the antihypertensive activities of Niguldipine.	Approved, Investigational
Unoprostone	Unoprostone may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Urapidil	Urapidil may increase the hypotensive activities of Niguldipine.	Investigational
Valsartan	Valsartan may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Niguldipine.	Approved
Vincamine	Niguldipine may increase the hypotensive activities of Vincamine.	Experimental
Vinpocetine	Niguldipine may increase the hypotensive activities of Vinpocetine.	Investigational
Voriconazole	The therapeutic efficacy of Voriconazole can be increased when used in combination with Niguldipine.	Approved, Investigational
Xipamide	Niguldipine may increase the hypotensive activities of Xipamide.	Experimental
Xylometazoline	Xylometazoline may increase the hypotensive activities of Niguldipine.	Approved, Investigational
Yohimbine	Yohimbine may decrease the antihypertensive activities of Niguldipine.	Approved, Investigational, Vet Approved
Zofenopril	Niguldipine may increase the hypotensive activities of Zofenopril.	Experimental

Food Interactions

Not Available

References

General References

Boer R, Grassegger A, Schudt C, Glossmann H: (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1989 May 11;172(2):131-45. [PubMed:2548881]

External Links

PubChem Compound: 60602
PubChem Substance: 310265142
ChemSpider: 54630
BindingDB: 50453799
ChEBI: 103931
ChEMBL: CHEMBL405355
Wikipedia: Niguldipine

Clinical Trials

Clinical Trials: Not Available

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.000113 mg/mL	ALOGPS
logP	6.27	ALOGPS
logP	5.6	ChemAxon
logS	-6.7	ALOGPS
pKa (Strongest Acidic)	19.47	ChemAxon
pKa (Strongest Basic)	9.59	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	111.01 Å²	ChemAxon
Rotatable Bond Count	12	ChemAxon
Refractivity	185.9 m³·mol^-1	ChemAxon
Polarizability	66.15 Å³	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Diphenylmethanes
Direct Parent: Diphenylmethanes
Alternative Parents: Phenylpiperidines / Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives
show 10 more
Substituents: Diphenylmethane / Phenylpiperidine / Nitrobenzene / Dihydropyridinecarboxylic acid derivative / Nitroaromatic compound / Aralkylamine / Dihydropyridine / Piperidine / Hydropyridine / Dicarboxylic acid or derivatives
show 30 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: Not Available

Targets

Details1. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Antagonist

General Function: Protein heterodimerization activity
Specific Function: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name: ADRA1A
Uniprot ID: P35348
Uniprot Name: Alpha-1A adrenergic receptor
Molecular Weight: 51486.005 Da

References

Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8. [PubMed:8183249]

Drug created on October 23, 2015 11:02 / Updated on March 02, 2018 05:26

Niguldipine

Identification

Structure for DB09239 (Niguldipine)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References